PTC Therapeutics Inc. (PTCT)
The price, the headline numbers and the latest news, in one place.
PTC Therapeutics Inc. (PTCT) Stock Price, Analysis & Data
No data available
| Bid | 69.83 |
| Market Cap | 5.85B |
| Revenue (ttm) | 1.01B |
| Net Income (ttm) | -38.38M |
| 0.55 | |
| -0.67 | |
| n/a | |
| 28.04 | |
| P/B (ttm) | -35.31 |
| P/S (ttm) | 5.80 |
| Earnings Date | Nov 5, 2026 |
| Ask | 89.34 |
| Volume | 691,054 |
| Avg. Volume (20D) | 1,686,782 |
| Open | 71.08 |
| Previous Close | 71.81 |
| Day's Range | 69.61 - 71.23 |
| 52-Week Range | 49.38 - 90.87 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the tr...
Financial Performance
In 2025, PTC Therapeutics's revenue was 1.73B, an increase of 114.51% compared to the previous year's 806.78M. Earnings were 682.64M, a decrease of -287.9%.
Financial StatementsEarnings Surprise
- Revenue of $360.52M misses estimates by $0, with 101.55% YoY growth.
- EPS of 0.92 exceeds estimates by 0.58, with 210.84% YoY growth.
Analysts project revenue of ... Upgrade
1 week ago · GuruFocus.com
Wells Fargo Sees Up to 52% Upside in 2 StocksThe bank is looking well beyond mega-cap technology.
